Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheter-Related Infections | 4 | 2023 | 270 | 1.640 |
Why?
|
| Nephrostomy, Percutaneous | 2 | 2023 | 55 | 1.560 |
Why?
|
| Urinary Tract Infections | 2 | 2023 | 321 | 1.170 |
Why?
|
| Immunocompromised Host | 3 | 2020 | 698 | 1.020 |
Why?
|
| Pneumocystis carinii | 1 | 2020 | 20 | 0.750 |
Why?
|
| beta-Glucans | 1 | 2020 | 34 | 0.740 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2020 | 68 | 0.730 |
Why?
|
| Nocardia Infections | 1 | 2020 | 34 | 0.720 |
Why?
|
| Acalculous Cholecystitis | 1 | 2019 | 5 | 0.710 |
Why?
|
| Cholecystitis, Acute | 1 | 2019 | 17 | 0.700 |
Why?
|
| Urinary Catheterization | 1 | 2018 | 117 | 0.630 |
Why?
|
| Opportunistic Infections | 1 | 2019 | 223 | 0.620 |
Why?
|
| Cough | 1 | 2018 | 116 | 0.610 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 437 | 0.480 |
Why?
|
| Neoplasms | 7 | 2023 | 15193 | 0.480 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2013 | 151 | 0.400 |
Why?
|
| Catheterization | 1 | 2013 | 410 | 0.400 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 257 | 0.390 |
Why?
|
| Catheters, Indwelling | 1 | 2013 | 374 | 0.380 |
Why?
|
| Pneumonia | 1 | 2013 | 751 | 0.290 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 849 | 0.250 |
Why?
|
| Anti-Bacterial Agents | 4 | 2021 | 2992 | 0.210 |
Why?
|
| Salmonella Infections | 1 | 2021 | 40 | 0.200 |
Why?
|
| Patients | 1 | 2023 | 245 | 0.190 |
Why?
|
| Nocardia | 1 | 2020 | 10 | 0.190 |
Why?
|
| Plesiomonas | 1 | 2019 | 4 | 0.180 |
Why?
|
| Fusariosis | 1 | 2019 | 8 | 0.180 |
Why?
|
| Proteoglycans | 1 | 2020 | 259 | 0.170 |
Why?
|
| Fusarium | 1 | 2019 | 50 | 0.170 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 254 | 0.170 |
Why?
|
| Bordetella bronchiseptica | 1 | 2018 | 5 | 0.170 |
Why?
|
| Bordetella Infections | 1 | 2018 | 4 | 0.170 |
Why?
|
| Thorax | 1 | 2020 | 213 | 0.170 |
Why?
|
| Liver Failure | 1 | 2019 | 140 | 0.160 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2019 | 158 | 0.160 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 490 | 0.160 |
Why?
|
| Hepatitis B virus | 1 | 2019 | 217 | 0.160 |
Why?
|
| Fatal Outcome | 1 | 2020 | 829 | 0.150 |
Why?
|
| Abdomen | 1 | 2019 | 332 | 0.150 |
Why?
|
| Nitroglycerin | 1 | 2017 | 43 | 0.150 |
Why?
|
| Adenine | 1 | 2019 | 631 | 0.140 |
Why?
|
| Gastroenteritis | 1 | 2019 | 300 | 0.140 |
Why?
|
| Coinfection | 1 | 2018 | 189 | 0.140 |
Why?
|
| Central Venous Catheters | 1 | 2017 | 98 | 0.140 |
Why?
|
| Bacteremia | 1 | 2021 | 689 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2019 | 649 | 0.130 |
Why?
|
| Humans | 14 | 2023 | 261506 | 0.130 |
Why?
|
| Neutropenia | 1 | 2019 | 968 | 0.130 |
Why?
|
| Aged | 7 | 2020 | 70117 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 7551 | 0.130 |
Why?
|
| Clostridium | 1 | 2014 | 25 | 0.130 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 164 | 0.120 |
Why?
|
| Piperidines | 1 | 2019 | 1035 | 0.120 |
Why?
|
| Middle Aged | 7 | 2023 | 86204 | 0.120 |
Why?
|
| Skin | 1 | 2019 | 1259 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 1039 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2019 | 834 | 0.110 |
Why?
|
| Meningitis | 1 | 2013 | 112 | 0.110 |
Why?
|
| Inpatients | 1 | 2018 | 678 | 0.110 |
Why?
|
| Female | 8 | 2020 | 141928 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2023 | 37905 | 0.110 |
Why?
|
| Adult | 5 | 2019 | 77950 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 4971 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2017 | 691 | 0.100 |
Why?
|
| Biopsy | 1 | 2019 | 3443 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 29902 | 0.090 |
Why?
|
| Recurrence | 1 | 2018 | 4758 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 4744 | 0.090 |
Why?
|
| Male | 8 | 2019 | 123000 | 0.090 |
Why?
|
| Quality of Life | 1 | 2022 | 4532 | 0.080 |
Why?
|
| Lung | 1 | 2019 | 3151 | 0.080 |
Why?
|
| Young Adult | 2 | 2018 | 21445 | 0.080 |
Why?
|
| Texas | 1 | 2018 | 6311 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2019 | 32848 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 2390 | 0.070 |
Why?
|
| Brain | 1 | 2020 | 4113 | 0.070 |
Why?
|
| Salmonella | 1 | 2021 | 35 | 0.050 |
Why?
|
| Risk Factors | 1 | 2018 | 17523 | 0.050 |
Why?
|
| Nephrotomy | 1 | 2017 | 5 | 0.040 |
Why?
|
| Enterobacter | 1 | 2017 | 20 | 0.040 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2017 | 16 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2013 | 16273 | 0.040 |
Why?
|
| Candida glabrata | 1 | 2017 | 45 | 0.040 |
Why?
|
| Health Personnel | 1 | 2022 | 625 | 0.040 |
Why?
|
| Candida albicans | 1 | 2017 | 175 | 0.030 |
Why?
|
| Biofilms | 1 | 2017 | 199 | 0.030 |
Why?
|
| Spores, Bacterial | 1 | 2014 | 49 | 0.030 |
Why?
|
| Catheterization, Central Venous | 1 | 2017 | 354 | 0.030 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 308 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2022 | 1423 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2017 | 446 | 0.030 |
Why?
|
| Adolescent | 1 | 2013 | 31252 | 0.030 |
Why?
|
| Necrosis | 1 | 2014 | 580 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 1155 | 0.030 |
Why?
|
| Child | 1 | 2013 | 29154 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2017 | 1203 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 6086 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 6009 | 0.010 |
Why?
|
| Sarcoma | 1 | 2014 | 1725 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 10035 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 12873 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 7702 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 59536 | 0.010 |
Why?
|